Princeton researchers have developed a new tool to speed the discovery of advanced materials known as metal organic ...

Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...

Structure Therapeutics (GPCR) just moved its obesity pipeline up a gear by kicking off a first in human Phase 1 trial for ACCG-2671, its oral amylin receptor agonist targeting metabolic disease. See ...

Decodo’s residential proxy servers aren’t the cheapest, but it has one of the largest and most high-quality pools around, and ...